Article
(FDA) advisory committee members voted 16-8 in favor of a mandatory registry, a plan which was also supported by Hoffman-LaRoche and generic isotretinoin manufacturers.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.